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AbstrAct
Objectives This study aimed to describe how canine diabetes 
mellitus (CDM) is monitored in primary care practice (PCP) and 
to report outcomes.
Design Retrospective case review.
Setting PCP.
Participants 40 dogs of 22 different pedigrees and five 
crossbreeds. Median age at diagnosis was nine years and 
six months (eight years six months to 10 years five months). 
Dogs were diagnosed with CDM between January 1, 2008 
and December 30, 2012 and remained with the practice to the 
study end or until death.
Primary and secondary outcome measures Stability 
achievement and death or euthanasia. Consultations for each 
dog were identified and recorded through records collected 
from the PCP (January 1, 2008 to December 30, 2012).
Results A median of three consultations per dog occurred 
in the first month, subsequently falling to a median of one 
consultation every 19 days thereafter. After the first month 
postdiagnosis, weight and single blood glucose concentrations 
were most frequently recorded at 66.8 and 42 per cent of 
consultations respectively and a blood glucose curve was 
performed infrequently (17.4 per cent). Serum biochemistry 
was measured at 8 per cent of consultations and urine culture 
at only 0.8 per cent. Median survival time (MST) for all dogs 
was eight months (2–21 months). Eighteen dogs stabilised 
within three months of diagnosis and their MST was 20.5 
months, (10.25–25.75 months), significantly longer than the 
22 dogs not achieving stability within three months (MST 2.5 
months, 0–5.5 months) (P<0.001). Those dogs not surviving 
beyond the first month had significantly fewer consultations 
than those still alive (P<0.005).
Conclusions This pilot study indicates dogs with CDM 
managed solely in PCP experience limited monitoring 
tests and have lower MST than reported in the literature. 
Recruitment of a larger cohort of CDM cases from a larger 
number of PCP will help determine whether these results 
accurately represent this demographic and verify if infrequent 
testing is associated with a poor outcome. Importantly, 
prospective evaluation of decision-making around monitoring 
CDM in PCP is required, to help determine the effectiveness 
and feasibility of more frequent monitoring strategies, such 
as those recommended by the American Animal Hospital 
Association, particularly to influence MST.
IntRODuCtIOn
Canine diabetes mellitus (CDM) is a common 
endocrine disorder (prevalence of 0.3 per 
cent) and in most dogs is insulin dependent.1–3 
CDM therapy aims to alleviate clinical signs 
and improve quality of life, avoiding acute 
complications, such as diabetic ketoacidosis 
and iatrogenic hypoglycaemia and limiting 
chronic complications such as infections and 
cataracts.4–6 Assessment of treatment efficacy 
is important, particularly assessing glycaemic 
control; good control implies effective treat-
ment. A clinician’s choice of tests to monitor 
glycaemic control is often based on their 
perceived strengths and weaknesses, as well 
as individual experience.7–9 The American 
Animal Hospital Association (AAHA) have 
produced guidelines for managing CDM,10 
which recommend consultations every 7–10 
days after diagnosis with a blood glucose curve 
(BGC) until clinical signs are controlled. The 
guidelines then advise quarterly consulta-
tions, a nadir blood glucose (BG) concentra-
tion and fructosamine or a BGC, along with 
biannual haematology, biochemistry and 
urinalysis (with culture). While guidelines 
may be beneficial in the approach to moni-
toring CDM, the way clinicians in primary 
care practice (PCP) routinely monitor CDM 
remains largely unknown. There are no 
specific studies assessing the monitoring prac-
tices of CDM in PCP and much of the recent 
available literature on CDM has originated 
from tertiary referral practice or research 
animals.11–13 It is likely that these populations 
of dogs are different, along with the moni-
toring practices, due to a combination of 
disease demographic, financial limitations, 
owner and clinician preferences and the 
implementation of practice protocols.
Coupled with this, considerable variation 
exists in previous reports of CDM median 
survival times (MST): from 18 months to five 
years.14–16 The aims of this pilot study were to 
describe how CDM is monitored in a single 
large PCP and to report the outcomes of 
affected dogs therein, and by extension, deter-
mine whether this suggests significant differ-
ences to the literature from referral settings 
and justifies further large-scale evaluation.
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MethODS
Individual electronic patient records of diabetic dogs 
were collected retrospectively over five years (January 
1, 2008 to December 30, 2012) from a large UK PCP 
(>20 primary care veterinarians with nine branches). For 
inclusion, dogs had to be diagnosed with CDM, including 
as a minimum, identification of persistent hyperglycaemia 
and glycosuria. Included dogs were treated with Canin-
sulin within the study period, remaining with the prac-
tice until study completion or until death/euthanasia. 
Animals diagnosed before January 1, 2008 or with incom-
plete records were excluded. For each dog, all appoint-
ments were evaluated and retrieved data were collected 
into an electronic spreadsheet (Microsoft Office Excel 
2010). All diagnostic tests were recorded at each visit 
along with bodyweight (kg), clinical signs, test results 
and changes in insulin dose (iu/kg). Dogs were classi-
fied as stable if their clinical signs resolved, their weight 
was maintained/increased and their insulin dose was 
unchanged, with an acceptable fructosamine concentra-
tion (<500 μmol/l) or an acceptable BGC (online supple-
mentary appendix 1). If a dog died or was euthanased, 
its age, duration of survival after diagnosis and cause of 
death were recorded. Any reasons for constraints over 
monitoring were recorded, such as aggression, finances 
or poor compliance.
Graphical figures were produced using a commercial 
statistical programme (GraphPad Prism V.5). Descriptive 
data are presented as the total number and percentage 
or median with the IQR in parenthesis. Continuous 
data were tested for normality with an Anderson-Darling 
test and assessed with a commercial software package 
(GraphPad Prism V.5) using a Student’s t test or Mann-
Whitney rank-sum test for non-parametric data. Statistical 
significance was set at P<0.05 and dogs were not censored 
for survival analysis if alive at study completion.
ReSultS
Forty dogs met the inclusion criteria (detailed in 
figure 1), which comprised five crossbreed dogs and 
22 different purebreeds, the most frequent being West 
Highland white terriers,5 Yorkshire terriers,4 rottweilers3 
and dachshunds.3 There were 20 neutered (50 per cent) 
and three entire (7.5 per cent) females, 10 neutered (25 
per cent) and seven entire (17.5 per cent) males. Median 
age at diagnosis was nine years and six months (eight 
years six months to 10 years five months).
A total of 105 consults were recorded for the 40 dogs 
in the first month after diagnosis, with a median of three 
(two to four) consultations per dog (table 1). Eight dogs 
(20 per cent) were euthanased during the first month, 
two of these dogs had two monitoring appointments, four 
dogs had one monitoring appointment, one dog died 
and one was euthanased before their first monitoring 
appointment. There was a significant difference in the 
number of consultations between the 32 dogs alive after 
the first month and the eight deceased dogs (P<0.0005), 
three (two to four) months and 1.38 (one to two) months, 
respectively. In this first month after diagnosis, clinical 
signs were recorded at 79 (75.2 per cent) consultations, 
a single blood glucose (SBG) was performed at 76 (72.4 
per cent), a BGC at 26 (24.8 per cent), weight at 49 (46.7 
per cent) and fructosamine at 5 (4.8 per cent). No other 
tests were performed in this time period.
After the first month, until the end of the study period 
there were 367 consultations for 32 dogs, with a median 
of 7 (4–20) per dog. Each dog attended a consultation 
a median of every 19 (6–30) days. The longest period 
between consultations for any individual dog was 100 
days. Clinical signs were recorded at 292 (77 per cent) 
consultations and weight was recorded significantly 
more frequently than the first month, at 248 (66.8 per 
cent) consultations (P<0.008). SBG and fructosamine 
Figure 1 Review of Caninsulin logs from the primary care 
practice (PCP) records, highlighting exclusion criteria.
Table 1 The number of appointments (Apt) for all dogs 
included into the study, within the first month following 
diagnosis of CDM. The dogs are divided into alive or dead at 
one month after diagnosis
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were measured at 156 (42 per cent) and 73 (19.8 per 
cent) consultations, respectively (figure 2). A BGC was 
performed following 64 (17.4 per cent) consultations 
and the median BGC duration throughout the study was 
9.5 hours (8–24), having a median number of glucose 
concentrations recorded on each occasion of 6.5–8 Serum 
biochemistry was performed at 31 (8 per cent), haema-
tology at 18 (4.9 per cent) and urine culture at 3 (0.8 
per cent) consultations. Home measurement of BG was 
recorded at one consultation. Over this period, other than 
records of weight and clinical signs, 14 of these 32 alive 
dogs (43.8 per cent) had SBG or fructosamine measured 
and no other monitoring tests were performed.
Twenty-three dogs (57.5 per cent) were considered clin-
ically stable before the end of the study period, attaining 
the criteria indicated in the Methods section—resolution 
of clinical signs, stable to increasing weight and compat-
ible diagnostic results; 10 dogs had an appropriate BGC, 
4 had fructosamine concentrations suggesting excellent 
control, 5 good and 4 fair. Of the dogs not stabilising 
within the study period, one dog remained alive at study 
completion, the other 16 dogs were euthanased/died 
without confirmation of stability at any time point. The 
MST for all dogs (including 10 alive at study completion) 
was 8.5 months (2–21 months). There were 18 dogs that 
stabilised within three months of diagnosis, their MST 
was 20.5 months (10.25–25.75 months) (figure 3). This 
was significantly longer than the MST of 2.5 months 
(0–5.5 months) for the 22 dogs that were not stabilised 
within three months (P<0.001). A further three dogs 
stabilised after three months, their survival ranged from 
10 months to three years five months (figure 3).
The median age at death, for the 30 dogs not alive at 
study completion, was 10 years six months, (nine years 
two months to 11 years 11 months). No postmortems 
were performed, however clinical records indicated that 
21/30 dogs were euthanased or died due to complica-
tions arising from CDM, the remainder were either not 
recorded or unrelated to CDM, such as identification 
of additional conditions or neoplasia. Further tests or 
appointments were declined in four of the 21 dogs that 
deteriorated due to CDM and in four of the nine dogs 
with an unrelated illness or unknown cause.
DISCuSSIOn
This pilot study provides an interesting insight into 
how CDM is monitored in a large multicentre PCP. The 
results show that there is considerable variation in moni-
toring of CDM compared with the available guidelines, 
in particular, the type and frequency of the monitoring. 
A striking finding is the MST after diagnosis, which is 
shorter than previously reported in the literature. Taking 
into account that the survival of animals embarking on 
treatment for CDM will impact on the willingness to treat, 
this finding is very important. The median consultation 
frequency of three times in the first month, and thereafter, 
once approximately every month, is consistent with some 
suggested guidelines4 9 10; however, there was considerable 
variability, with some dogs not being seen for extended 
periods. It is difficult to retrospectively determine 
whether this is due to owners’ perception of their dog’s 
stability during the extended periods, or from veterinary 
advice. While perhaps the consultation frequency could 
be perceived as reasonable or comparable to guidelines, 
this study indicates infrequent diagnostic testing during 
the follow-up period for CDM in PCP and a variable selec-
tion of conducted tests. The finding that those dogs not 
surviving beyond the first month had significantly fewer 
consultations than those remaining alive (P<0.0005) 
warrants further investigation in a larger cohort as this 
may be an important observation influencing outcome. 
The infrequent use of BGC is striking, being performed 
at just 17.4 per cent of consultations after the first month, 
when considered to be an important method of assess-
ment by the AAHA.10 The retrospective nature of this 
pilot study makes the factors influencing the choice to 
perform a BGC unknown but considerations would 
be: individual clinician preferences, along with patient 
factors such as cost, compliance, available resources and 
time. BGCs have their own limitations, such as variability, 
high cost, and they are impacted by stress, which may be a 
reason for low utility.17 Importantly, however, it appeared 
from the clinical records that BGCs were predominantly 
Figure 2 The total number of monitoring techniques used 
after the first month of the study period.
Figure 3 A Kaplan-Meier curve of survival, months 
after diagnosis, divided into dogs stabilised and those 
remaining unstable within less than three months. ACTH, 
adrenocorticotropic hormone; BG, blood glucose. 
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performed when cases were considered unstable, though 
the degree of instability was however difficult to discern 
in each case. An important aspect to highlight was the 
short period over which the BGCs were performed in 
the clinic. Fundamental to performing a BGC is its value 
in providing information to guide changes in managing 
CDM. In many cases the period of assessment of the BGC 
was perhaps too short to be of maximal clinical value (eg, 
five hours) especially as key aspects, such as evaluating the 
glucose nadir and duration of action, would have been 
missed. This is therefore an important aspect for further 
study, particularly to discern whether BGCs completed 
in PCP offer value for money to the clients and facilitate 
optimal decision-making.
The frequent use of an SBG is surprising given the 
limited information it reportedly provides especially if 
not taken at the nadir.17 Due to the retrospective nature 
of the study, the timing of the SBG was unclear for the 
majority of occasions and therefore its clinical utility in 
this respective case series remains unknown. Even when 
the nadir is known, the practical benefit is questionable 
due to the variability of glycaemic curves.17 Despite this, 
the use of SBG at the nadir is part of the recommenda-
tions of the AAHA10 and this may be due to a combina-
tion of cost and practicality. Understanding more about 
the rationale behind this frequent use of SBG is there-
fore important as slight modifications in the timing of 
the SBG may improve their perceived utility (according 
to the AAHA).
Home monitoring of BG is supported by the current 
AAHA recommendations and its lack of utility here is 
surprising, as it can be a practical technique and provide 
an accurate representation of glycaemic control.18 Urine 
glucose measurements were also not reported for any 
dogs. Future prospective evaluations of CDM monitoring 
should include the utility of these techniques.
The reason for increased weight measurements after 
the first month is unclear, though this is undoubt-
edly important as it provides invaluable insight into 
glycaemic control19 and importantly confers no extra 
cost to the client. It was of interest that fructosamine was 
not measured within the first month but was measured 
thereafter. While the reason for this was not appreciated 
from the clinical records, this could be due to perceived 
importance of using fructosamine to review longer term 
stability.
In this pilot study, urine cultures were conducted infre-
quently and in each case were completed during periods 
of clinical instability, suggesting this may have been 
the reason for the test to have been conducted. Given 
their occult nature, urinary tract infections (UTI) may 
have been missed and because UTIs are well recognised 
as impacting on stability of CDM,4 20 their infrequent 
use in this cohort is surprising and may have effected 
outcomes. A valuable question to answer in a larger scale 
prospective study would be: What influences the decision 
to perform urine cultures in CDM? Haematology and 
serum biochemistry were also measured infrequently in 
this population (figure 1), which is interesting, as these 
would be considered ‘routine’ test in PCP, especially 
considering the importance of comorbidities in influ-
encing diabetic stability and outcome.21 When examining 
this in terms of the AAHA guidelines, regular screening 
using these particular parameters is advocated. It was 
difficult to establish why these tests were used so infre-
quently. Occasionally, free-text information was available 
within the clinical notes but this was insufficient in the 
majority of cases to reveal the rationale. This highlights 
a limitation, as with other retrospective studies; under-
standing the rationales behind decision-making. Ulti-
mately, the outcome of any clinical research is to better 
inform future clinical decisions, and due to a current lack 
of understanding decision-making practices in CDM, it 
makes improvements difficult. This point alone clearly 
demonstrates the value of a PCP-based prospective 
follow-up study, which collects these important details on 
a large enough scale to have a robust relationship with 
PCP in general.
The MST after diagnosis is shorter than previously 
described,4 14–16 however, as survival analysis in previous 
studies varies, a direct comparison becomes difficult. 
For example, Foster16 and Doxey et al (1986) excluded 
30 and 33 per cent of cases that died within one month 
of diagnosis, giving mean survivals of 1.75 years and 18 
months, respectively. Excluding dogs that did not survive 
the first month from our cohort increases the MST to 
16 months. By contrast, the 55 per cent stabilisation 
rate in our cohort compares favourably with previous 
reports.14 16 One particular interesting and potentially 
valuable result, which requires further evaluation, is 
that achieving stability, especially within three months, 
was associated with improved survival; this has not been 
previously reported. An additional aspect, which cannot 
be appreciated from this retrospective study, is owner 
perception of quality of life in affected dogs. The liter-
ature would suggest that owner satisfaction of diabetic 
dogs is variable and as low as 50 per cent are satisfied.22 It 
would therefore be a key aspect of a prospective study to 
determine the degree of satisfaction and perhaps more 
importantly whether this is linked to stability and survival 
times and a number of quality of life tools are available 
for this purpose.23
In conclusion, the findings from this pilot study show 
interesting variance of monitoring practices and survival 
from much of the literature regarding CDM and from the 
AAHA guidelines in 2010,10 which have recently updated 
these in 2018.24 The reasons for this substantial varia-
tion from the currently accepted CDM data and guide-
lines justify a larger study and prospective evaluation of 
monitoring practices are necessary. The findings from 
this particular PCP may be generally applicable to the 
majority of PCPs but recruitment of a larger number of 
PCPs is the essential next step in determining this. As part 
of a prospective study, evaluating the use and perceived 
effectiveness and practicalities of the AAHA (or other 
such) guidelines would also be valuable. If we tenuously 
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extrapolate from this pilot study cohort, survival of CDM 
in PCP has not improved in the UK since 1985, this alone 
suggests prospective studies in PCP using the guidelines 
are essential to establish whether their use improves 
stability and survival of CDM and if not, what does?
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